CTX112
Phase 2Biologic
CRISPR TherapeuticsCTX112 is one of 7 biologic programs targeting Warm Autoimmune Hemolytic Anemia (wAIHA). It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Relapsed or Refractory B-Cell Malignancies
#DrugCompanyPhaseTrials
1Zynlonta
Akero TherapeuticsPhase 2
Fludara
SanofiPhase 1
Cytoxan
BBaxter Healthcare Corporation
Phase 1
CTX112
CRISPR TherapeuticsPhase 2
Rapamycin
MMaastricht Radiation Oncology
Phase 1
LP-168
GGuangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed or Refractory B-cell Malignancies1 trial
Progressive Multiple Sclerosis (PMS)1 trial
SLE (Systemic Lupus)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CTX112. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company